- Home
- FGI vs SLXN Comparison
FGI vs SLXN Comparison
Compare FGI & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- SLXN
- Stock Information
- Founded
- FGI 1987
- SLXN 2008
- Country
- FGI United States
- SLXN Israel
- Employees
- FGI N/A
- SLXN N/A
- Industry
- FGI Industrial Specialties
- SLXN
- Sector
- FGI Industrials
- SLXN
- Exchange
- FGI Nasdaq
- SLXN NYSE
- Market Cap
- FGI 8.0M
- SLXN 5.0M
- IPO Year
- FGI 2022
- SLXN N/A
- Fundamental
- Price
- FGI $0.87
- SLXN $1.26
- Analyst Decision
- FGI
- SLXN Strong Buy
- Analyst Count
- FGI 0
- SLXN 1
- Target Price
- FGI N/A
- SLXN $9.00
- AVG Volume (30 Days)
- FGI 6.0K
- SLXN 32.1M
- Earning Date
- FGI 03-19-2025
- SLXN 02-21-2025
- Dividend Yield
- FGI N/A
- SLXN N/A
- EPS Growth
- FGI N/A
- SLXN N/A
- EPS
- FGI N/A
- SLXN N/A
- Revenue
- FGI $127,180,460.00
- SLXN N/A
- Revenue This Year
- FGI $11.39
- SLXN N/A
- Revenue Next Year
- FGI $6.26
- SLXN N/A
- P/E Ratio
- FGI N/A
- SLXN N/A
- Revenue Growth
- FGI 7.71
- SLXN N/A
- 52 Week Low
- FGI $0.70
- SLXN $0.21
- 52 Week High
- FGI $1.85
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- FGI 55.71
- SLXN N/A
- Support Level
- FGI $0.86
- SLXN N/A
- Resistance Level
- FGI $0.90
- SLXN N/A
- Average True Range (ATR)
- FGI 0.03
- SLXN 0.00
- MACD
- FGI 0.00
- SLXN 0.00
- Stochastic Oscillator
- FGI 66.67
- SLXN 0.00
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. It offers sanitaryware, bath furniture, shower systems, customer kitchen cabinetry, and other accessory items. It is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. its revenue is generated by sanitaryware. Geographically it operates in the United States, Canada, Europe, Rest of the World, and the majority of its revenue comes from the United States.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.